BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 14658586)

  • 1. Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer: a clinical study and literature review.
    Hall DJ; Martin DA; Kincaid K
    Eur J Gynaecol Oncol; 2003; 24(6):481-9. PubMed ID: 14658586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
    Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
    Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
    Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
    Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
    Fleming GF; Filiaci VL; Bentley RC; Herzog T; Sorosky J; Vaccarello L; Gallion H
    Ann Oncol; 2004 Aug; 15(8):1173-8. PubMed ID: 15277255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
    Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
    Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
    J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
    Levitan N; Dowlati A; Craffey M; Tahsildar H; MacKay W; McKenney J; Remick SC
    Lung Cancer; 1998 Dec; 22(3):227-34. PubMed ID: 10048475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy of endometrial cancer revisited].
    Fehr MK; Wight E; Haller U
    Gynakol Geburtshilfliche Rundsch; 1999; 39(3):110-20. PubMed ID: 10420053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
    Pierga JY; DiƩras V; Beuzeboc P; Dorval T; PalangiƩ T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
    Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer.
    Budd GT; Atiba J; Silver RT; Palmer G; Armstrong S; Otto K; Presant C
    J Cancer Res Clin Oncol; 1999; 125(8-9):500-4. PubMed ID: 10480343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study.
    Glisson B; Komaki R; Lee JS; Shin DM; Fossella F; Murphy WK; Kurie J; Perez-Soler R; Schea R; Vadhan-Raj S
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):331-6. PubMed ID: 9457817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer.
    Yahata H; Hirakawa T; Fujita T; Ariyoshi K; Sonoda K; Amada S; Kobayashi H; Nakano H
    Int J Clin Oncol; 2004 Aug; 9(4):317-21. PubMed ID: 15375709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix.
    Eralp Y; Saip P; Sakar B; Tas F; Aydiner A; Topuz E
    Eur J Gynaecol Oncol; 2003; 24(3-4):323-6. PubMed ID: 12807249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.
    Talbot SM; Westerman DA; Grigg AP; Toner GC; Wolf M; Bishop J; McKendrick J; Zalcberg J; Levi J; Fox RM; Green MD
    Ann Oncol; 1999 Aug; 10(8):907-14. PubMed ID: 10509151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
    Burke TW; Stringer CA; Morris M; Freedman RS; Gershenson DM; Kavanagh JJ; Edwards CL
    Gynecol Oncol; 1991 Mar; 40(3):264-7. PubMed ID: 2013451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
    Piccart MJ; Bruning P; Wildiers J; Awada A; Schornagel JH; Thomas J; Tomiak E; Bartholomeus S; Witteveen PO; Paridaens R
    Ann Oncol; 1995 Sep; 6(7):673-7. PubMed ID: 8664188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.